Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Itanapraced (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors CereSpir; Chiesi
- 10 Dec 2012 New trial record
- 21 Nov 2012 Status changed from not yet recruiting to withdrawn prior to recruitment according to ClinicalTrials.gov.